The data taken as a whole indicates that OKN-007 may possibly be an effective anti-cancer agent for some patients with pHGGs by inhibiting cell proliferation and angiogenesis, potentially via the PDGFRα pathway, and could be considered as an additional therapy for pediatric brain tumor patients. This evidence concerns the gene PDGFRA and cancer.